Can Fatty Liver Disease Be Reversed? What Treatments Work

Research-informed explainer — last updated April 12, 2026

Yes, fatty liver disease can be reversed — but not always, and the stage of your disease matters more than almost anything else. In the early stages, losing weight and changing your diet can bring liver fat levels back to normal. In more advanced stages involving scarring (fibrosis), reversal is harder but still possible with the right treatment — and for the first time, there is now an FDA-approved drug proven to reduce fibrosis in patients with the most serious form of the disease.

This explainer draws on research from five liver specialists in the Convene directory. Mary Rinella at UChicago Medicine led the AASLD practice guidance for fatty liver disease and helped develop the new clinical terminology now used worldwide. Scott Friedman at Mount Sinai is one of the leading researchers on liver fibrosis — specifically how scar tissue forms, and under what conditions it can reverse. Eric Lawitz at the Texas Liver Institute served as principal investigator on pivotal Phase 3 drug trials for fatty liver disease. Naim Alkhouri at Cleveland Clinic was a lead investigator on the MAESTRO-NASH trial that resulted in the first FDA-approved drug for fatty liver scarring. Wajahat Mehal at Yale directs the Yale Fatty Liver Disease and Metabolic Health programs.

What fatty liver disease actually is

Fatty liver disease goes by several names depending on what's happening in the liver. The current preferred terminology, established through a multisociety Delphi consensus process in 2023 that Mary Rinella led, uses the term MASLD — metabolic dysfunction-associated steatotic liver disease [4]. This replaced the older term NAFLD (nonalcoholic fatty liver disease) to better reflect that the condition is driven by metabolic factors like obesity, diabetes, and insulin resistance.

The spectrum looks like this: liver fat accumulation alone (MASLD) is the mildest stage. When that fat accumulation triggers inflammation and cell damage, the condition is called MASH (metabolic dysfunction-associated steatohepatitis — previously called NASH). MASH with fibrosis is the stage where serious liver damage is occurring and long-term risk of cirrhosis and liver failure rises sharply.

About 25% of adults worldwide have some degree of fatty liver. Of those, roughly 20% have MASH, and a subset of those will progress to advanced fibrosis or cirrhosis without treatment [5].

How it is diagnosed

Most people with fatty liver disease have no symptoms — the liver doesn't have pain nerves, so early damage is often silent. The condition is typically discovered on a blood test (elevated liver enzymes) or an imaging study done for another reason.

Diagnosis involves several steps. Blood tests check liver enzymes (ALT, AST), and your doctor may calculate a score called FIB-4 that estimates your fibrosis stage using your age, platelet count, and enzyme levels. Imaging — either ultrasound, MRI, or an advanced technique called MR elastography — can measure liver stiffness as a proxy for fibrosis. In some cases, a liver biopsy is needed to confirm the diagnosis and stage the disease accurately, though non-invasive alternatives are increasingly replacing biopsy for routine assessment.

The AASLD practice guidance developed by Mary Rinella's team established the recommended diagnostic framework, including when biopsy is appropriate and when non-invasive testing is sufficient [1].

What "reversal" means at each stage

Whether and how much the liver can recover depends on how far along the disease is.

Early fatty liver (MASLD without inflammation): This stage is highly reversible. Reducing liver fat through weight loss, dietary change, or exercise typically brings enzyme levels back to normal and reduces liver fat on imaging. The damage at this stage is not structural — no scar tissue has formed, so the liver recovers well.

MASH without significant fibrosis: Still reversible in most patients. Clinical trials involving Scott Friedman's group showed that structured weight loss of 7-10% body weight significantly reduces features of MASH on liver biopsy, including inflammation, ballooning injury, and fat accumulation [8]. In one randomized trial, patients who lost 7% or more of body weight were significantly more likely to achieve MASH resolution — and some achieved it with even modest weight loss.

MASH with fibrosis (stages 1-3): This is where things get more complicated. Scar tissue in the liver is laid down by specialized cells called hepatic stellate cells. Research from Scott Friedman at Mount Sinai established the fundamental biology: stellate cells activate in response to liver injury, and they can also deactivate — meaning fibrosis is not necessarily permanent [6, 7]. With sufficient sustained improvement in the underlying injury, fibrosis can partially reverse. This is what makes the new drug treatments meaningful: if a drug can resolve MASH and reduce the ongoing injury, fibrosis has a chance to regress.

Cirrhosis (stage 4 fibrosis): At this stage, reversal is limited. The architectural distortion of the liver is substantial, and while some improvement in liver function can occur with treatment, full reversal is not expected. Prevention — treating MASH before cirrhosis develops — is far more effective than treating after.

Lifestyle treatment: what actually works

Weight loss remains the most reliably effective intervention for fatty liver disease, with the magnitude of benefit scaling with the amount of weight lost [8].

Losing 3-5% of body weight reduces liver fat. Losing 7-10% improves MASH inflammation and injury. Losing more than 10% can reduce fibrosis by at least one stage in a meaningful percentage of patients. These figures come from multiple controlled trials and are reflected in the AASLD guidelines [1].

The type of diet matters less than the amount of weight lost, but there is some evidence that Mediterranean-pattern eating — high in vegetables, olive oil, fish, and legumes, low in saturated fat and refined sugars — has benefits for liver fat beyond what weight loss alone explains.

Exercise helps independently of weight loss. Aerobic exercise reduces liver fat, and resistance training may have additional benefits on insulin sensitivity. The current recommendation is at least 150 minutes of moderate aerobic activity per week.

Alcohol makes fatty liver disease worse even at modest levels. Current guidance is to minimize alcohol in anyone with MASLD and avoid it entirely in anyone with MASH or fibrosis.

Drug treatment: what's new and what's available

Until 2024, there was no FDA-approved drug specifically for fatty liver disease. That changed in March 2024 when the FDA approved resmetirom (Rezdiffra) for adults with MASH and moderate-to-advanced liver fibrosis (stages 2 and 3).

The MAESTRO-NASH trial, a Phase 3 randomized controlled study that Naim Alkhouri helped lead, enrolled 966 patients with biopsy-confirmed MASH and fibrosis [9]. The key results: at the 80 mg dose, 25.9% of patients achieved MASH resolution without worsening fibrosis, compared to 14.2% in the placebo group. At the 100 mg dose, 29.9% achieved resolution. Fibrosis improvement of at least one stage occurred in 24.2% (80 mg), 25.9% (100 mg), and 14.2% (placebo). Resmetirom works by activating a receptor in liver cells that increases fat metabolism.

GLP-1 receptor agonists — drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — are also showing substantial benefits for fatty liver disease, largely through their effects on weight loss and metabolic improvement. Eric Lawitz's group was involved in pivotal Phase 3 tirzepatide data for MASH, which showed approximately 51% fibrosis improvement rates — the most dramatic liver fibrosis reversal figures ever published for a drug. These data supported regulatory submissions for a liver-specific indication. While GLP-1 agonists are currently approved for diabetes and weight loss rather than for MASH specifically, many liver specialists now consider them a central tool for patients with both conditions.

GI side effects (nausea, diarrhea) are the main tolerability concern with GLP-1 agonists for most patients.

Other drug classes under active investigation include PPAR agonists (lanifibranor, which showed reduced inflammation scores in a Phase 2b trial [10]) and FGF21 analogues. The pipeline is active — multiple Phase 3 results are expected in the next two to three years.

Who is at highest risk and shouldn't wait

Not everyone with fatty liver disease will progress. But certain factors significantly raise your risk of getting worse:

• Type 2 diabetes or insulin resistance
• Obesity (especially central/abdominal obesity)
• Metabolic syndrome
• Fibrosis already present on imaging or biopsy
• Older age
• Certain genetic variants (PNPLA3 and TM6SF2 mutations raise risk substantially)

Research from Wajahat Mehal's group at Yale identified how gut microbiome changes — specifically, dysbiosis driven by inflammasome activation — contribute to NAFLD progression, suggesting that the gut-liver connection is part of why metabolic disease promotes liver injury [10].

If you have MASH with any fibrosis, seeing a hepatologist — not just a primary care provider — is worthwhile. The treatment decisions at that stage, including whether to consider resmetirom or pursue a GLP-1 drug, require specialist input.

Questions to ask your doctor

• What stage of fatty liver disease do I have, and how was that determined?
• Do I need a liver biopsy, or can imaging and blood tests give us what we need?
• How much weight loss would I need to achieve to meaningfully improve my liver?
• Am I a candidate for resmetirom, and does my insurance cover it?
• Would a GLP-1 medication like semaglutide or tirzepatide be appropriate for me?
• How often should I have follow-up imaging or labs to track whether things are improving or worsening?
• At what point would I need to see a liver transplant specialist?